Literature DB >> 25280033

Do elevated serum IgM levels have to be included in probable diagnosis criteria of patients with ataxia-telangiectasia?

E Azarsiz1, N E Karaca1, N C Gunaydin1, N Gulez2, C Ozturk3, G Aksu1, F Genel2, N Kutukculer1.   

Abstract

Ataxia-telangiectasia (AT) is a rare multisystem, neurodegenerative genetic disorder that is characterised by progressive neurological abnormalities, oculocutaneous telangiectasias and immunodeficiency. Delay in diagnosis or misdiagnosis is probable due to its wide clinical heterogeneity in infancy. Recurrent sinopulmonary infections are often the only presenting symptom and usually patients have decreased immunoglobulins. A total 10% of patients who present with decreased serum immunoglobulin G and A and with normal or elevated immunoglobulin M levels are often misdiagnosed as hyperimmunoglobulin M syndrome. Definitive diagnosis is made if a patient with progressive cerebellar ataxia has a disease causing mutation on the ATM gene. Ataxia-telangiectasia guideline of the European Society for Immunodeficiencies defines the probable diagnosis criteria. We evaluated twenty ataxia-telangiectasia patients (mean age 13.8±4.1 years) retrospectively who were followed-up for a mean of 38.6±27.0 months. Twelve patients had a family history of consanguinity. A total of 80% patients suffered from various infections. Neoplasms occurred in three of them. Patients showed immunological abnormalities as low IgG (45%), low IgA (65%) and elevated IgM (60%) levels. CD3+CD4+ T lymphocyte frequency was low in 45% patients. The mean AFP concentration at the diagnosis was 191.9±140.1 ng/mL and the raised IgM values did not show any statistically significant relationship with high AFP concentrations. Frequency of the elevated IgM concentrations in (60%) patients raises the concerns about thinking this finding has to be accepted as a probable diagnosis criterium.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25280033     DOI: 10.1177/039463201402700312

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  5 in total

1.  Ataxia telangiectasia in Turkey: multisystem involvement of 91 patients.

Authors:  Hacer Akturk; Murat Sutcu; Ayper Somer; Sanem Piskin; Manolya Acar; Meral Ozmen; Umut Altinoglu; Burak Tatli; Nuran Salman
Journal:  World J Pediatr       Date:  2017-01-25       Impact factor: 2.764

2.  Ataxia Telangiectasia Diagnosed on Newborn Screening-Case Cohort of 5 Years' Experience.

Authors:  Amarilla B Mandola; Brenda Reid; Raga Sirror; Rae Brager; Peter Dent; Pranesh Chakroborty; Dennis E Bulman; Chaim M Roifman
Journal:  Front Immunol       Date:  2019-12-20       Impact factor: 7.561

3.  Genetic Risk Variants for Class Switching Recombination Defects in Ataxia-Telangiectasia Patients.

Authors:  Parisa Amirifar; Mahya Mehrmohamadi; Mohammad Reza Ranjouri; Seyed Mohammad Akrami; Nima Rezaei; Ali Saberi; Reza Yazdani; Hassan Abolhassani; Asghar Aghamohammadi
Journal:  J Clin Immunol       Date:  2021-10-10       Impact factor: 8.542

4.  The natural history of ataxia-telangiectasia (A-T): A systematic review.

Authors:  Emily Petley; Alexander Yule; Shaun Alexander; Shalini Ojha; William P Whitehouse
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.752

5.  Elevated IgM levels as a marker for a unique phenotype in patients with Ataxia telangiectasia.

Authors:  Alexander Krauthammer; Avishay Lahad; Lior Goldberg; Ifat Sarouk; Batia Weiss; Raz Somech; Michalle Soudack; Itai M Pessach
Journal:  BMC Pediatr       Date:  2018-06-04       Impact factor: 2.125

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.